TABLE 2.
Characteristics of MASH model treated with elobixibat and cholestyramine
| Parameters | Basal diet (group BD) | AMLM (group MASH) | AMLM+Elobixibat (group E) | AMLM+Colestyramine (group C) | AMLM+Elobixibat+colestyramine (group EC) |
|---|---|---|---|---|---|
| Food intake (g/d) | 3.09±0.09 | 3.22±0.05 | 3.38±0.16 | 3.38±0.11 | 3.16±0.04 |
| Water intake (mL/d) | 5.16±0.28 | 3.53±0.41a | 6.23±0.28b | 4.17±0.15 | 3.8±0.12 |
| Stool water content (%) | 51.75±2.95 | 36.71±1.72a | 58.54±1.85c | 32.63±1.92 | 40.81±1.12 |
| Stool particle count (particle number/day/mouse) | 81.88±4.52 | 50.38±2.94a | 89.00±2.71c | 39.63±2.43b | 50.25±2.85 |
| Body weight (g) | 29.2±0.6 | 43.3±0.6a | 38.8±1.3c | 39.4±0.8c | 33.8±0.7c |
| Liver weight (g) | 1.3±0.03 | 4.2±0.18a | 3.2±0.19c | 3.7±0.11c | 2±0.10c |
| Epididymal adipose tissue weight (g) | 0.6±0.07 | 2.3±0.11a | 2.0±0.14 | 2.1±0.16 | 1.2±0.12c |
| HOMA-IR | 0.41±0.16 | 2.94±0.71a | 1.50±0.47 | 1.42±0.49 | 0.81±0.45b |
| Total cholesterol (mg/dL) | 83.6±2.4 | 260.4±10.9a | 224.6±17.3 | 235.5±15.3 | 126.1±12.9c |
| AST (IU/L) | 57.5±11.2 | 292.375±37.9a | 169±14.9b | 275±63.8 | 111.3±26.7b |
| ALT (IU/L) | 21.8±11.2 | 239.5±37.9a | 94.9±14.9c | 197.3±63.8 | 32.6±26.7c |
| Free fatty acid (uEQ/L) | 723.8±58.6 | 1061.1±50.5a | 781.6±60.0c | 824±55.0c | 426.8±47.0c |
Note: Data are presented as the mean±SE (n=6–8). Significance was determined using Student t test.
a
p<0.05 versus BD group.
b
p<0.05 versus MASH group.
c
p<0.01 versus MASH group.
Abbreviations: ALT, alanine aminotransferase; AMLM, amylin liver metabolic dysfunction-associated steatohepatitis; AST, aspartate aminotransferase; BD, basal diet; C, cholestyramine; E, elobixibat; EC, elobixibat and cholestyramine; HOMA-IR, homeostasis model assessment of insulin resistance; MASH, metabolic dysfunction-associated steatohepatitis.